PhotoCure Submits European Marketing Authorisation Application for Metvix® PDT for the Treatment of "High Risk" BCC
PhotoCure ASA has submitted its second marketing authorisation application (MAA) for Metvix® PDT for the treatment of basal cell carcinoma (BCC), a non-melanoma skin cancer. The marketing application was made to the Health Authorities in Sweden who will act as the Reference Member State in the European Mutual Recognition Procedure, leading to EU-wide approval. PhotoCure ASA submitted its first MAA for Metvix® PDT for treatment of pre-cancerous skin lesions, actinic keratosis (AK) in May 2000.This second MAA, for the treatment of BCC, is the result of PhotoCure's continuous development of